ZNTL today
$1.75-$0.14 (-7.41%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourExpanding
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $6.95
Key levels
Resistance$2.25
Resistance$1.96
Support$1.31
Latest news & SEC filings
AnalystWedbush raises Zentalis Pharmaceuticals to Outperform with $6 price target
EarningsZentalis Pharmaceuticals Posts Q3 2026 Results
AnalystZentalis Pharmaceuticals receives Outperform rating from Wedbush
All ZNTL news →About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals develops azenosertib, an experimental oral WEE1 inhibitor, for treating solid tumors including ovarian malignancies. Its lead focus is platinum-resistant ovarian disease that tests positive for Cyclin E1, studied in mid- and late-stage trials, along with a combination study of azenosertib plus bevacizumab as maintenance treatment. The company is based in the United States and relies on outside partners for manufacturing and clinical trial operations.
Based on the company's 10-K filed Mar 26, 2026.
Nasdaq · Healthcare
Zentalis Pharmaceuticals, Inc. (ZNTL)
What Is the Price Target for ZNTL?
SEPT Low Target
$8.00
SEPT Mid Target
$10.00
SEPT High Target
$11.00
Analyst Consensus
$10.00
Is ZNTL a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ZNTL.
Start Free Trial →Is ZNTL Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$8.80
10
Moat Score
NONE
1/9
Piotroski Score
-5.6
Altman Z-Score
What Is Smart Money Doing with ZNTL?
Insider Signal
SELLING
1 buys / 9 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Bruns Ingmar | officer | Buy | 9,727 | $21K | Sep 30, 2026 |
| Campbell Shannon | director | Buy | 114,200 | - | May 26, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ZNTL Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
18.03%
FCF Growth YoY
26.8%
Revenue Trend
UNKNOWN
Dark Pool Trades for ZNTL
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ZNTL, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:49:04 | $1.75 | 1,900 | $$3K | BUY |
| 17:39:41 | $1.75 | 1,000 | $$2K | SELL |
| 17:29:32 | $1.76 | 5,657 | $$10K | SELL |
| 17:29:24 | $1.77 | 1,000 | $$2K | BUY |
| 17:22:47 | $1.77 | 1,833 | $$3K | BUY |
5 dark pool trades shown · $$20K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Zentalis Pharmaceuticals, Inc. (ZNTL) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ZNTL — frequently asked questions
What is ZNTL stock price today?
Zentalis Pharmaceuticals, Inc. (ZNTL) is at $1.75, down 7.41% (-$0.14) at the Nov 12, 2026 close.
Why is ZNTL stock moving today?
Latest ZNTL news — Nov 10, 2026: Wedbush raises Zentalis Pharmaceuticals to Outperform with $6 price target · Nov 10, 2026: Zentalis Pharmaceuticals Posts Q3 2026 Results
What is the ZNTL price target?
The average analyst price target for ZNTL is $10.00, ranging from $8 to $11, based on 5 analysts.
What do analysts rate ZNTL?
Analyst ratings for ZNTL: 0 Buy, 8 Hold, 0 Sell — consensus Hold.
Did ZNTL beat earnings?
ZNTL last reported on Aug 6, 2026: EPS -$0.59 vs -$0.49 expected — a miss of 20.4%.
Does ZNTL pay a dividend?
ZNTL does not currently pay a dividend.
What are ZNTL support and resistance levels?
Support: $1.31. Resistance: $1.96, $2.25, $2.47.
What are insiders doing with ZNTL?
Insider activity: SELLING, 1 buys and 9 sells in the last 90 days.
What is the latest news on ZNTL?
Nov 10, 2026: Wedbush raises Zentalis Pharmaceuticals to Outperform with $6 price target · Nov 10, 2026: Zentalis Pharmaceuticals Posts Q3 2026 Results · Nov 10, 2026: Zentalis Pharmaceuticals receives Outperform rating from Wedbush